However, another study demonstrated that low-dose rosiglitazone (2 mg) exerted a marked anti-inflammatory effect over 6 weeks in T2DM patients, reducing SAA levels by 29% while increasing adiponectin and decreasing resistin levels, without any detectable changes in plasma glucose, free fatty acids (FFA), or insulin concentrations [49]. Here, SAA1 is linked to type 2 diabetes mellitus.